Corporate Snapshot
Aeterna Zentaris Inc. is a growing oncology and endocrine therapy focused biopharmaceutical company with proven expertise in drug discovery, development and commercialization. The Company's broad 20 product pipeline leverages six different therapeutic approaches, including Luteinizing Hormone Releasing Hormone (LHRH) antagonists and signal transduction inhibitors. The lead LHRH antagonist compound, cetrorelix, is currently marketed for in vitro fertilization under the brand name Cetrotide®. Cetrorelix is also in late-stage clinical development for endometriosis and benign prostatic hyperplasia (BPH). The lead signal transduction inhibitor compound, perifosine, is an orally-active AKT inhibitor that is in several Phase II trials for multiple cancers. Aeterna Zentaris owns 50.3% of Atrium Biotechnologies Inc. (TSX: ATB.sv), a leading developer, manufacturer and marketer of value-added products for the cosmetics, pharmaceutical, chemical and nutritional industries.
* The Corporate Snapshot was last updated on November 13, 2006.
Latest Research
Quarterly
Update
2006-11-13
Click to View
Quarterly
Update
2006-08-16
Click to View
Quarterly
Update
2006-06-12
Click to View
Quarterly
Update
2006-03-13
Click to View
Quarterly
Update
2005-11-16
Click to View
Quarterly
Update
2005-05-25
Click to View
Quarterly
Update
2005-03-22
Click to View
Executive
Informational
Overview
2004-05-13
Click to View
* An earlier Executive Informational Overview was published on May 6, 2003. A copy of this report can be obtained by emailing eio@crystalra.com.
Stock Information (AEZS-NASDAQ)